Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 7 May 2013
[DOI: 10.1126/scisignal.2003741]

Supplementary Materials for:

A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53

Manabu Kurokawa,* Jiyeon Kim, Joseph Geradts, Kenkyo Matsuura, Liu Liu, Xu Ran, Wenle Xia, Thomas J. Ribar, Ricardo Henao, Mark W. Dewhirst, Wun-Jae Kim, Joseph E. Lucas, Shaomeng Wang, Neil L. Spector, Sally Kornbluth*

*Corresponding author. E-mail: manabu.kurokawa{at}dartmouth.edu (M.K.); sally.kornbluth{at}duke.edu (S.K.)

This PDF file includes:

  • Fig. S1. p53 status of the cell lines used in this study.
  • Fig. S2. MI-219 can reverse lapatinib resistance.
  • Fig. S3. SRC abundance in the cell lines used in this study.
  • Fig. S4. The SRC inhibitor dasatinib does not affect MDM2 protein abundance.
  • Fig. S5. BT474 cells with acquired lapatinib resistance prevent mitochondrial cytochrome c release in response to lapatinib treatment.
  • Fig. S6. Mcl-1 abundance increases in SKBR3 cells with acquired lapatinib resistance following lapatinib treatment.
  • Fig. S7. Mcl-1 is stabilized in lapatinib-resistant SKBR3 cells.
  • Fig. S8. Ubiquitin aldehyde does not prevent the failure to degrade Mcl-1 in the resistant cells.
  • Fig. S9. Unaltered abundance of Apaf-1.
  • Fig. S10. CK2-mediated phosphorylation of HSP90β at Ser226 and Ser255.
  • Fig. S11. PP5 is stabilized in lapatinib-resistant AU565 cells.
  • Fig. S12. Biochemical purification of the PP5-targeted E3 ligase.
  • Fig. S13. Overexpression of HUWE1 leads to reduced abundance of PP5 and Mcl-1.
  • Fig. S14. CAS degradation in lapatinib-resistant AU565 cells.
  • Fig. S15. Enhanced CAS polyubiquitylation in lapatinib-resistant SKBR3 cells.
  • Fig. S16. Schematic diagram of the CAS protein sequence.
  • Fig. S17. Densitometric analysis of HUWE1 and MDM2 abundance after lapatinib treatment.
  • Fig. S18. Schematic representation of HUWE1 protein and the amino acid sequence surrounding the MDM2 binding motif.
  • Fig. S19. HUWE1 and MDM2 interact in cells.
  • Fig. S20. Densitometric analysis of the abundance of HUWE1, MDM2, CAS, PP5, and Mcl-1 upon lapatinib–Nutlin-3a cotreatment.
  • Fig. S21. Nutlin-3 can reverse lapatinib resistance in rAU565 xenografts.
  • Table S1. Biomarker status of breast cancer cell lines used in this study.
  • References (44, 45)

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 3.75 MB


Citation: M. Kurokawa, J. Kim, J. Geradts, K. Matsuura, L. Liu, X. Ran, W. Xia, T. J. Ribar, R. Henao, M. W. Dewhirst, W.-J. Kim, J. E. Lucas, S. Wang, N. L. Spector, S. Kornbluth, A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53. Sci. Signal. 6, ra32 (2013).

© 2013 American Association for the Advancement of Science


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882